Related Experiment Videos
Immune-based therapies for prostate cancer
Douglas G McNeel1, Miroslav Malkovsky
1Department of Medicine, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA. dm3@medicine.wisc.edu
Immunology Letters
|December 9, 2004
Summary
Immunotherapy offers a promising new avenue for treating prostate cancer, a major cause of death. Recent advancements in active and passive immunotherapy suggest a hopeful future when combined with traditional treatments.
Area of Science:
- Oncology
- Immunology
Background:
- Prostate cancer is a significant cause of morbidity and mortality in the United States.
- Early studies over four decades ago indicated potential benefits of immunological approaches for prostate cancer treatment.
Purpose of the Study:
- To explore advancements in immune-based therapy for prostate cancer.
- To review current immunotherapy approaches and their potential combination with conventional therapies.
Main Methods:
- Review of animal and clinical studies.
- Analysis of information gathered over the last two decades on immune-based therapy.
- Evaluation of current clinical trials and future treatment strategies.
Main Results:
- Immunological approaches have evolved significantly over the past two decades.
- Both passive and active immunotherapy strategies are being developed for prostate cancer.
- Current trials show promise, especially when immunotherapy is combined with conventional treatments.
Conclusions:
- The field of immune-based therapy for prostate cancer has advanced considerably.
- Combining immunotherapy with conventional therapies offers a hopeful outlook for improved patient outcomes.
- Further research and clinical trials are essential to fully realize the potential of immunotherapy in prostate cancer treatment.